Venetoclax to prevent differentiation syndrome in APL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests adding venetoclax to standard treatment to prevent a serious side effect called differentiation syndrome in people with newly diagnosed acute promyelocytic leukemia (APL). Patients must be healthy enough to receive intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed APL that has not been treated yet.
- You must be considered fit enough for intensive chemotherapy based on heart, lung, kidney, and liver function.
- You cannot have an active, uncontrolled infection or active bleeding in vital organs.
- You must not have a history of drug or alcohol abuse that would affect the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This study looks at how the drug venetoclax works in people newly diagnosed with acute myeloid leukemia (AML). It helps doctors understand the right dose for better results.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
Hear when a new Acute Promyelocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.